The authors of the randomized CLOTBUST ER trial of Cerevast Therapeutics Inc.’s sonothrombolysis system believe the pulsed-wave intracranial ultrasound technology could be used to improve the exposure of intracranial thrombus to alteplase (recombinant tissue plasminogen activator) and potentially facilitating early reperfusion.
But the 90-day results from CLOTBUST ER trial did not show a benefit of the therapy in patients with acute ischemic stroke.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?